Vai al contenuto principale
Logo Università
Logo di Dipartimento di Scienza e Tecnologia del Farmaco

Dipartimento di Scienza e Tecnologia del Farmaco

Dipartimento di Scienza e Tecnologia del Farmaco

Seguici su

Logo di Dipartimento di Scienza e Tecnologia del Farmaco
Foto gruppo

"Farmacogenomica tumorale"

"Cancer PharmacoGenomics (CPG)"

Componenti

  1. Gallicchio Margherita (Coordinatore/Coordinatrice)
  2. Boscaro Valentina (Ricercatore/Ricercatrice)
Fotografia

Settore ERC

LS7_7 - Pharmacology and toxicology

Attività

Studio dell’effetto di farmaci, composti di nuova sintesi ed estratti naturali su pathways di segnale coinvolti nella vitalità e sopravvivenza di diverse linee cellulari umane tumorali e non tumorali.

  • Caratterizzazione farmacologica di cannabinoidi e composti derivati dal cannabidiolo su linee cellulari umane
  • Caratterizzazione farmacologica di nuovi inibitori dell’attivazione di NLRP3 in THP-1 differenziate
  • Caratterizzazione di composti duali con attività inibitoria su EGFR in linee cellulari di carcinoma colorettale con diverse mutazioni sulla via di segnale di EGFR
  • Valutazione degli effetti tossici di residui di farmaci come contaminanti delle acque marine dell’Antartide su diversi tipi di linee cellulari
  • Valutazione ecotossicologica degli effetti di filtri UV chimici su differenti tipi di linee cellulari
  • Valutazione dell’attività farmacologica di inibitori di AKR1C su linee cellulari di carcinoma colorettale, da soli o in associazione a farmaci antitumorali utilizzati in clinica per il trattamento del tumore del colon retto

  • Saggi di vitalità cellulare: quantificazione dell’ATP utilizzando un saggio in luminescenza; MTT
  • Saggi Elisa per misurare il rilascio di citochine dalle cellule
  • Western Blot per valutare l’espressione e l’attivazione di proteine in pathway di segnale coinvolti nella vitalità e sopravvivenza cellulare
  • Valutazione della morte cellulare per priroptosi attraverso la misurazione del rilascio di lattato deidrogenasi da THP-1 differenziate

All'interno del DSTF:

SynBioMed (SBM)

MeDSynth

Biochemistry and Molecular Biology (BMB)

Analytical Chemistry

Organic chemistry

 
Study of the effect of drugs, new synthetized compounds and natural extracts on signaling pathways involved in viability and survival of tumor and not tumor human cell lines. 

 

  • Pharmacological characterization of cannabinoids and cannabidiol-derived compounds in human cell lines
  • Pharmacological characterization of new inhibitors of NLRP3 activation in differentiated THP-1
  • Characterization of dual compounds with inhibitory activity on EGFR on coloncancer cell lines harboring different mutations on EGFR signaling pathway
  • Evaluation of toxic effects of drug contaminants present in Antarctic-seawater on different type of cell lines
  • Ecotoxicological evaluationof effects of Organic UV filters on different type of cell lines
  • Evaluation of pharmacological activity of AKR1C inhibitors on colon cancer tumor cell lines, alone or in association with anticancer drugs used in the treatment of colorectal cancer

  • Cell viability assays: quantification of ATP using a luminescence assay; MTT
  • ELISA to quantify cytokine release from cells
  • Western blot to study the expression and activation of proteins in signaling pathway involved in cell viability and survival
  • Evaluation of pyroptotic cell death by the quantification of lactate dehydrogenase release from differentiated THP-1

Inside the Department:

SynBioMed (SBM)

MeDSynth

Biochemistry and Molecular Biology (BMB)

Analytical Chemistry

Organic chemistry


Prodotti della ricerca

  1. Boscaro V, Rivoira M, Sgorbini B, Bordano V, Dadone F, Gallicchio M, Pons A, Benetti E, Rosa AC. (2022) Evidence-Based Anti-Diabetic Properties of Plant from the Occitan Valleys of the Piedmont Alps. Pharmaceutics 14(11) [DOI  PMID]
  2. Boscaro V, Barge A, Deagostino A, Ghibaudi E, Laurenti E, Marabello D, Diana E, Gallicchio M. (2021) Effects of Vanadyl Complexes with Acetylacetonate Derivatives on Non-Tumor and Tumor Cell Lines. Molecules (Basel, Switzerland) 26(18) [DOI  PMID]
  3. Gastaldi S, Boscaro V, Gianquinto E, Sandall CF, Giorgis M, Marini E, Blua F, Gallicchio M, Spyrakis F, MacDonald JA, Bertinaria M. (2021) Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor. Molecules (Basel, Switzerland) 26(13) [DOI  PMID]
  4. Lolli ML, Carnovale IM, Pippione AC, Wahlgren WY, Bonanni D, Marini E, Zonari D, Gallicchio M, Boscaro V, Goyal P, Friemann R, Rolando B, Bagnati R, Adinolfi S, Oliaro-Bosso S, Boschi D. (2019) Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3. ACS medicinal chemistry letters 10(4) 437-443 [DOI  PMID]
  5. Rosa AC, Benetti E, Gallicchio M, Boscaro V, Cangemi L, Dianzani C, Miglio G. (2019) Analyzing Cysteine Site Neighbors in Proteins to Reveal Dimethyl Fumarate Targets. Proteomics 19(4) e1800301 [DOI  PMID]
  6. Boscaro V, Boffa L, Binello A, Amisano G, Fornasero S, Cravotto G, Gallicchio M. (2018) Antiproliferative, Proapoptotic, Antioxidant and Antimicrobial Effects of Sinapis nigra L. and Sinapis alba L. Extracts. Molecules (Basel, Switzerland) 23(11) [DOI  PMID]
  7. Lovisari M, Volpi G, Marabello D, Cadamuro S, Deagostino A, Diana E, Barge A, Gallicchio M, Boscaro V, Ghibaudi E. (2017) EPR and photophysical characterization of six bioactive oxidovanadium(IV) complexes in the conditions of in vitro cell tests. Journal of inorganic biochemistry 170 55-62 [DOI  PMID]
  8. Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. (2016) Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer research 76(15) 4504-15 [DOI  PMID]
  9. Serpe L, Gallicchio M, Canaparo R, Dosio F. (2014) Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Pharmacogenomics and personalized medicine 7 31-42 [DOI  PMID]
  10. Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F. (2013) BRAF V600E is a determinant of sensitivity to proteasome inhibitors. Molecular cancer therapeutics 12(12) 2950-61 [DOI  PMID]
  11. Sgarbossa S, Diana E, Marabello D, Deagostino A, Cadamuro S, Barge A, Laurenti E, Gallicchio M, Boscaro V, Ghibaudi E. (2013) Synthesis, characterization and cell viability test of six vanadyl complexes with acetylacetonate derivatives. Journal of inorganic biochemistry 128 26-37 [DOI  PMID]
  12. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404) 532-6 [DOI  PMID]
  13. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. The Journal of clinical investigation 120(8) 2858-66 [DOI  PMID]
  14. Di Nicolantonio F, Arena S, Gallicchio M, Bardelli A. (2010) Isogenic mutant human cells: a new tool for personalized cancer medicine. Cell cycle (Georgetown, Tex.) 9(1) 20-1 [DOI  PMID]
  15. Gallicchio M, Benetti E, Rosa AC, Fantozzi R. (2009) Tachykinin receptor modulation of cyclooxygenase-2 expression in human polymorphonuclear leucocytes. British journal of pharmacology 156(3) 486-96 [DOI  PMID]
  16. Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A. (2008) Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proceedings of the National Academy of Sciences of the United States of America 105(52) 20864-9 [DOI  PMID]
  17. Tripatara P, Patel NS, Collino M, Gallicchio M, Kieswich J, Castiglia S, Benetti E, Stewart KN, Brown PA, Yaqoob MM, Fantozzi R, Thiemermann C. (2008) Generation of endogenous hydrogen sulfide by cystathionine gamma-lyase limits renal ischemia/reperfusion injury and dysfunction. Laboratory investigation; a journal of technical methods and pathology 88(10) 1038-48 [DOI  PMID]
  18. Sivarajah A, Collino M, Yasin M, Benetti E, Gallicchio M, Mazzon E, Cuzzocrea S, Fantozzi R, Thiemermann C. (2009) Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock (Augusta, Ga.) 31(3) 267-74 [DOI  PMID]
  19. Gallicchio M, Benetti E, Rosa AC, Fantozzi R. (2008) Substance P-induced cycloxygenase-2 expression in polymorphonuclear cells. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 57 Suppl 1 S17-8 [DOI  PMID]
  20. Collino M, Thiemermann C, Mastrocola R, Gallicchio M, Benetti E, Miglio G, Castiglia S, Danni O, Murch O, Dianzani C, Aragno M, Fantozzi R. (2008) Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. Shock (Augusta, Ga.) 30(3) 299-307 [DOI  PMID]
  21. Murch O, Abdelrahman M, Collino M, Gallicchio M, Benetti E, Mazzon E, Fantozzi R, Cuzzocrea S, Thiemermann C. (2008) Sphingosylphosphorylcholine reduces the organ injury/dysfunction and inflammation caused by endotoxemia in the rat. Critical care medicine 36(2) 550-9 [DOI  PMID]
  22. Gallicchio M, Rosa AC, Dianzani C, Brucato L, Benetti E, Collino M, Fantozzi R. (2008) Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29). British journal of pharmacology 153(5) 870-8 [DOI  PMID]
  23. Dianzani C, Brucato L, Gallicchio M, Rosa AC, Collino M, Fantozzi R. (2008) Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression. British journal of pharmacology 153(6) 1153-61 [DOI  PMID]
  24. Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R. (2006) Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free radical biology & medicine 41(4) 579-89 [DOI  PMID]
  25. Dianzani C, Cavalli R, Zara GP, Gallicchio M, Lombardi G, Gasco MR, Panzanelli P, Fantozzi R. (2006) Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells. British journal of pharmacology 148(5) 648-56 [DOI  PMID]
  26. Dianzani C, Collino M, Gallicchio M, Di Braccio M, Roma G, Fantozzi R. (2006) Effects of anti-inflammatory [1, 2, 4]triazolo[4, 3-a] [1, 8]naphthyridine derivatives on human stimulated PMN and endothelial cells: an in vitro study. Journal of inflammation (London, England) 3 4 [DOI  PMID]
  27. Dianzani C, Collino M, Gallicchio M, Samaritani S, Signore G, Menicagli R, Fantozzi R. (2006) Evaluation of in-vitro anti-inflammatory activity of some 2-alkyl-4,6-dimethoxy-1,3,5-triazines. The Journal of pharmacy and pharmacology 58(2) 219-26 [DOI  PMID]
  28. Gallicchio M, Rosa AC, Benetti E, Collino M, Dianzani C, Fantozzi R. (2006) Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. British journal of pharmacology 147(6) 681-9 [DOI  PMID]
  29. Collino M, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C, Fantozzi R. (2006) Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. European journal of pharmacology 530(1-2) 70-80 [DOI  PMID]
  30. Grossini E, Avanzi G, Gallicchio M, Molinari C, Vacca G, Bellomo G. (2005) Regulation of Ca2+ movements by cyclovirobuxine D in ECV304 endothelial cells. Pharmacological research 52(2) 154-61 [DOI  PMID]
  31. Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, Bussolino F. (2005) Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 105(5) 1970-6 [DOI  PMID]
  32. Guidetti F, Grazioli S, Capelli F, Marini C, Gallicchio M, De Micheli D, Castello L, Sainaghi PP, Fra GP, Saglio G, Avanzi GC. (2004) Primitive hematopoietic stem cells shows a polyclonal pattern in myelodysplastic syndromes. Haematologica 89(1) 21-8 [PMID]
  33. Gaidano G, Capello D, Fassone L, Gloghini A, Cilia AM, Ariatti C, Buonaiuto D, Vivenza D, Gallicchio M, Avanzi GC, Prat M, Carbone A. (2000) Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 16(3) 215-24 [DOI  PMID]
  34. Capello D, Gaidano G, Gallicchio M, Gloghini A, Medico E, Vivenza D, Buonaiuto D, Fassone L, Avanzi GC, Saglio G, Prat M, Carbone A. (2000) The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. Leukemia 14(2) 285-91 [DOI  PMID]
  35. Gaidano G, Vivenza D, Forconi F, Capello D, Gloghini A, Bhatia K, Gutierrez M, Gallicchio M, Avanzi GC, Fassone L, Ariatti C, Buonaiuto D, Cingolani A, Saglio G, Tirelli U, Larocca LM, Dalla-Favera R, Carbone A. (2000) Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Genes, chromosomes & cancer 27(2) 177-82 [DOI  PMID]
  36. Avanzi GC, Gallicchio M, Saglio G. (1998) Hematopoietic growth factors in autologous transplantation. Biotherapy (Dordrecht, Netherlands) 10(4) 299-308 [DOI  PMID]
  37. Avanzi GC, Gallicchio M, Bottarel F, Gammaitoni L, Cavalloni G, Buonfiglio D, Bragardo M, Bellomo G, Albano E, Fantozzi R, Garbarino G, Varnum B, Aglietta M, Saglio G, Dianzani U, Dianzani C. (1998) GAS6 inhibits granulocyte adhesion to endothelial cells. Blood 91(7) 2334-40 [PMID]
  38. Avanzi GC, Gallicchio M, Cavalloni G, Gammaitoni L, Leone F, Rosina A, Boldorini R, Monga G, Pegoraro L, Varnum B, Aglietta M. (1997) GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. Experimental hematology 25(12) 1219-26 [PMID]
  39. Montemurro F, Gallicchio M, Aglietta M. (1997) [Prevention and treatment of febrile neutropenia]. Tumori 83(2 Suppl) S15-9 [PMID]

Ultimo aggiornamento: 11/05/2023 11:00
Location: https://www.dstf.unito.it/robots.html
Non cliccare qui!